PUBLICATION
Animal inflammation-based models of depression and their application to drug discovery
- Authors
- Ma, L., Demin, K.A., Kolesnikova, T.O., Kharsko, S.L., Zhu, X., Yuan, X., Song, C., Meshalkina, D.A., Leonard, B.E., Tian, L., Kalueff, A.V.
- ID
- ZDB-PUB-170818-5
- Date
- 2017
- Source
- Expert opinion on drug discovery 12(10): 995-1009 (Review)
- Registered Authors
- Kalueff, Allan V.
- Keywords
- Depression, affective disorders, animal models, drug discovery, neuroimmune modulation, neuroinflammation
- MeSH Terms
-
- Animals
- Antidepressive Agents/pharmacology
- Depression/drug therapy*
- Depression/physiopathology
- Disease Models, Animal
- Drug Design
- Drug Discovery/methods*
- Humans
- Inflammation/drug therapy*
- Inflammation/pathology
- Molecular Targeted Therapy
- PubMed
- 28816544 Full text @ Expert Opin. Drug Discov.
Citation
Ma, L., Demin, K.A., Kolesnikova, T.O., Kharsko, S.L., Zhu, X., Yuan, X., Song, C., Meshalkina, D.A., Leonard, B.E., Tian, L., Kalueff, A.V. (2017) Animal inflammation-based models of depression and their application to drug discovery. Expert opinion on drug discovery. 12(10):995-1009.
Abstract
Introduction Depression, anxiety and other affective disorders are globally widespread and severely debilitating human brain diseases. Despite their high prevalence and mental health impact, affective pathogenesis is poorly understood, and often remains recurrent and resistant to treatment. The lack of efficient antidepressants and presently limited conceptual innovation necessitate novel approaches and new drug targets in the field of antidepressant therapy. Areas covered: Herein, the authors discuss the emerging role of neuro-immune interactions in affective pathogenesis, which can become useful targets for CNS drug discovery, including modulating neuroinflammatory pathways to alleviate affective pathogenesis. Expert opinion: Mounting evidence implicates microglia, polyunsaturated fatty acids (PUFAs), glucocorticoids and gut microbiota in both inflammation and depression. It is suggested that novel antidepressants can be developed based on targeting microglia-, PUFAs-, glucocorticoid- and gut microbiota-mediated cellular pathways. In addition, the authors call for a wider application of novel model organisms, such as zebrafish, in studying shared, evolutionarily conserved (and therefore, core) neuro-immune mechanisms of depression.
Errata / Notes
This article is corrected by ZDB-PUB-220906-81 .
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping